



10.09.2026

**08:45 - 09:00**      **Welcome to the Molecular Analysis for Precision Oncology Congress 2026**      **Auditorium**  
Moderation: Lisa Derosa, France; Mariam Jamal-Hanjani, United Kingdom; Joaquin Mateo, Spain

**08:45 - 09:00**      **Opening session**  
Lisa Derosa<sup>1</sup>, Mariam Jamal-Hanjani<sup>2</sup>, Joaquin Mateo<sup>3</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, France,  
<sup>2</sup>UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom, <sup>3</sup>Vall d'Hebron  
University Hospital, Barcelona, Spain

**09:00 - 10:15**      **Aging and tumor genetics as determinants of myeloid immune dynamics in cancer**      **Auditorium**  
Moderation: Maria Casanova-Acebes, Spain; Arianna Calcinotto, Switzerland

**09:00 - 09:15**      **Tumor genetics modeling myeloid immunity**  
Vincenzo Bronte, University of Verona, Verona, Italy

**09:15 - 09:30**      **The role of neutrophils in BRCA-driven cancers**  
Arianna Calcinotto, IOR - Institute of Oncology Research, Bellinzona, Switzerland

**09:30 - 09:45**      **Circadian regulation of myeloid immunity in lung cancer**  
Maria Casanova-Acebes, CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

**09:45 - 10:00**      **Q&A**

**10:15 - 10:45**      **Coffee break**      **Foyer**

**10:45 - 12:00**      **Cancer evolution and metastasis**      **Auditorium**  
Moderation: Simone Zaccaria, United Kingdom

**10:45 - 11:00**      **Chromosomal instability dynamics in the decades preceding prostate cancer**  
Geoff Macintyre, CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

**11:00 - 11:15**      **Characterising the evolutionary dynamics of cancer proliferation in single-cell clones**  
Simone Zaccaria, UCL - University College London, London, United Kingdom

**11:15 - 11:30**      **Epigenetic cancer evolution**  
Celine Vallot, Institut Curie, Paris, France

**11:30 - 11:45**      **Linking cancer genotype to phenotypes through sequencing**  
Luuk Harbers, VIB-KULeuven Center for Cancer Biology (CCB), Leuven, Belgium

**11:45 - 12:00**      **Q&A**



|               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| 12:00 - 13:00 | <b>Lunch</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>Foyer</b>      |
| 12:15 - 13:00 | <b>YO Vesalius talk</b><br>Moderation: Emre Kocakavuk, Germany; Lucy Faulkner, United Kingdom                                                                                                                                                                                                                                                                                                                                                                                                         | <b>Gallery</b>    |
| 12:15 - 12:15 | <b>Introduction</b><br><u>Emre Kocakavuk</u> <sup>1</sup> , <u>Lucy Faulkner</u> <sup>2</sup> , <sup>1</sup> Universitätsklinikum Essen, Essen, Germany, <sup>2</sup> University of Cambridge, Cambridge, United Kingdom                                                                                                                                                                                                                                                                              |                   |
| 12:15 - 13:00 | <b>Opportunities and Risks of AI in Precision Oncology</b><br><u>Natasha Weiser</u> <sup>1</sup> , <u>Anton Henssen</u> <sup>2</sup> , <u>Benjamin Izar</u> <sup>3</sup> , <u>Celine Vallot</u> <sup>4</sup> , <sup>1</sup> Yale University, New Haven, United States of America, <sup>2</sup> Charité-Universitaetsmedizin Berlin - Campus Virchow Klinikum (CVK), Berlin, Germany, <sup>3</sup> Columbia University, New York, United States of America, <sup>4</sup> Institut Curie, Paris, France |                   |
| 13:15 - 15:15 | <b>Proffered paper session</b><br>Moderation: Mariam Jamal-Hanjani, United Kingdom; Caroline Dive, United Kingdom; Joaquin Mateo, Spain                                                                                                                                                                                                                                                                                                                                                               | <b>Auditorium</b> |
| 13:15 - 13:25 | <b>40 - Evolutionary landscape and non-canonical drivers of chromosomal instability, homologous recombination deficiency, and immune evasion in triple-negative breast cancer</b><br><u>Ieva Usaite</u> , UCL Cancer Institute - UCL - London's Global University, London, United Kingdom                                                                                                                                                                                                             |                   |
| 13:25 - 13:35 | <b>50 - Multi-omic profiling of serial plasma and autopsy tissue reveals the evolutionary basis of treatment resistance in lethal prostate cancer</b><br><u>Osvaldas Vainauskas</u> , UCL - University College London, London, United Kingdom                                                                                                                                                                                                                                                         |                   |
| 13:35 - 13:45 | <b>20 - National real-world tumour-normal WGS with target trial emulation identifies DNA repair phenotypes predicting platinum and PARP inhibitor benefit in high-grade ovarian cancers</b><br><u>Ionut Gabriel Funingana</u> , University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom                                                                                                                                                                                        |                   |
| 13:45 - 13:58 | <b>Wrap up and Q&amp;A</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                   |
| 13:58 - 14:08 | <b>60 - Identification of actionable cellular and molecular biomarkers in osteosarcoma using spatial transcriptomics</b><br><u>Gaël Moquin-Beaudry</u> , Institut Gustave Roussy, Villejuif, France                                                                                                                                                                                                                                                                                                   |                   |
| 14:08 - 14:18 | <b>90 - Advanced single cell multiomics to study the mechanisms of leukemia elimination and preservation of normal immune reconstitution by bispecific T cell engagers</b><br><u>Anna Gurevich-Shapiro</u> , The Weizmann Institute of Science, Rehovot, Israel                                                                                                                                                                                                                                       |                   |
| 14:18 - 14:31 | <b>Wrap up and Q&amp;A</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                   |



|               |                                                                                                                                                                                                                                                                                                    |                   |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| 14:31 - 14:41 | <b>10 - Generalisable immune classification for lung cancer diagnosis via a semantic multiple-instance learning pipeline applied to blood TCRseq repertoires of screening-eligible individuals</b><br><u>Petros Fessas</u> , UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom |                   |
| 14:41 - 14:51 | <b>70 - Epitranscriptomic liquid biopsy: A new paradigm for early detection and management of colorectal cancers</b><br><u>Alexandre David</u> , L'Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, France                                                                |                   |
| 14:51 - 15:01 | <b>30 - Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA</b><br><u>Andrew Retter</u> , Guys and St Thomas NHS Trust, London, United Kingdom                                                                                                            |                   |
| 15:01 - 15:15 | <b>Wrap up and Q&amp;A</b>                                                                                                                                                                                                                                                                         |                   |
| 15:15 - 15:45 | <b>Coffee break</b>                                                                                                                                                                                                                                                                                | <b>Foyer</b>      |
| 15:45 - 17:00 | <b>Molecular characterisation of cancer: Focus on extrachromosomal DNA</b><br>Moderation: Chris Bailey, United Kingdom                                                                                                                                                                             | <b>Auditorium</b> |
| 15:45 - 16:00 | <b>Origins and impact of ecDNA in cancers</b><br><u>Chris Bailey</u> , The Francis Crick Institute, London, United Kingdom                                                                                                                                                                         |                   |
| 16:00 - 16:15 | <b>ecDNA as a therapeutic vulnerability in cancer</b><br><u>Anton Henssen</u> , Charité-Universitaetsmedizin Berlin - Campus Virchow Klinikum (CVK), Berlin, Germany                                                                                                                               |                   |
| 16:15 - 16:30 | <b>Targetable liabilities of ecDNA-positive tumor cells</b><br><u>René Medema</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands                                                                                                                 |                   |
| 16:30 - 16:45 | <b>Interplay between transcription and DNA damage in ecDNA</b><br><u>Natasha Weiser</u> , Yale University, New Haven, United States of America                                                                                                                                                     |                   |
| 16:45 - 17:00 | <b>Q&amp;A</b>                                                                                                                                                                                                                                                                                     |                   |
| 17:00 - 18:00 | <b>ePoster Display session</b>                                                                                                                                                                                                                                                                     | <b>Gallery</b>    |
| 17:00 - 17:00 | <b>39eP - Targeted NGS-based assessment of microsatellite instability in colorectal cancer: Validation against pentaplex PCR and integrated analysis of a discordant case</b><br>Egor Veselovsky, P.A. Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation                      |                   |



- 17:00 - 17:00 **76eP - Pan-RAS inhibition by RMC-7977 suppresses growth and induces metabolic vulnerabilities in hepatocellular carcinoma**  
Somnath Ghosal, RKMVERI - Ramakrishna Mission Vivekananda Educational and Research Institute, Howrah, India
- 17:00 - 17:00 **103eP - Transcriptomic profiling reveals distinct biological subtypes in clinically defined triple-negative breast cancer**  
Tina Parusheva-Borsitzky, Higher Colleges of Technology, Abu Dhabi, United Arab Emirates
- 17:00 - 17:00 **114eP - Real-world clinical utility of molecular profiling for precision oncology in solid tumors: Experience from South India**  
Karthikeyan Kaliyamurthi, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth University, Pillayarkuppam, India
- 17:00 - 17:00 **137eP - Prognostic significance of neutrophil-to-lymphocyte ratio in patients responding to immunotherapy from a limited resource setting**  
Srikanth Anne, POSITRON Hospital, HARYANA, India
- 17:00 - 17:00 **141eP - Biomarker-based assessment of treatment response to *Terfezia boudieri* and its nanoformulation in breast cancer models**  
Roua Nouh, The American University in Cairo, Cairo, Egypt
- 17:00 - 17:00 **143eP - Association between baseline tumor burden and EGFR molecular characteristics in advanced NSCLC**  
Cristina Torres-Mallma, Oncocenter S.A.C. - Clinica Auna Oncosalud, Lima, Peru
- 17:00 - 17:00 **144eP - Analysis of mismatch-repair/microsatellite instability discordance in non-colorectal/endometrial tumors in patients with Lynch syndrome**  
Alexandra Lebedeva, OncoAtlas LLC, Moscow, Russian Federation
- 17:00 - 17:00 **146eP - Clinicopathologic correlates of oncotype dx results in HR-positive HER2-negative early breast cancer in Iraq**  
Rehab Thajeel, Ad-Diwaniyah Technical Institute, Al Diwaniyah, Iraq
- 17:00 - 17:00 **147eP - Is DNA- and RNA-based intratumoral heterogeneity informative of nCRT response in rectal cancer?**  
Ezequias Torres, Hospital Sirio-Libanés - Unidade Bela Vista, Sao Paulo, Brazil
- 17:00 - 17:00 **149eP - Ki-67 stratifies survival outcomes following streptozotocin-based chemotherapy in advanced neuroendocrine tumours: A real-world cohort study**  
Bahaaeldin Baraka, Nottingham City Hospital, Nottingham, United Kingdom
- 17:00 - 17:00 **150eP - Preclinical antitumor activity of lomitapide in glioblastoma**  
Ryuk Jun Kwon, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea



|                      |                                                                                                                                                                                                                                                                                     |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17:00 - 17:00        | <b>151eP - Real-world performance of fully automated PCR-based molecular testing for actionable biomarkers in NSCLC adenocarcinoma</b><br><u>Ana Magradze</u> , TSMU - Tbilisi State Medical University, Tbilisi, Georgia                                                           |
| 17:00 - 17:00        | <b>152eP - Thyroid cancer as a second primary malignancy in hereditary breast and ovarian cancer: Clinicogenomic findings from a real-world Latin American cohort</b><br><u>Iris Del Carmen Otoyá Fernandez</u> , INEN - Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru |
| 17:00 - 17:00        | <b>153eP - Analysis of telomerase reverse transcriptase gene polymorphism involved in cancer diseases in Algeria</b><br><u>Nabila Seridi</u> , USTHB - University of Science and Technology Houari Boumediene, Algiers, Algeria                                                     |
| 17:00 - 17:00        | <b>154eP - Development of novel therapeutic strategies for pancreatic cancer targeting GPCRs</b><br><u>Taiga Hirata</u> , Institute for Genetic Medicine - Hokkaido University, Sapporo, Japan                                                                                      |
| <b>17:00 - 18:00</b> | <b>Poster Display session</b> <span style="float: right;"><b>Gallery</b></span>                                                                                                                                                                                                     |
| 17:00 - 17:00        | <b>19P - CSF-based pre-operative diagnosis of CNS tumours</b><br><u>Huub Ent</u> , Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands                                                                                                                              |
| 17:00 - 17:00        | <b>21P - AI-based classification of histopathology with multi-omic data for risk stratification in medulloblastoma</b><br><u>Sai Anugna Sureddi</u> , Northumbria University, Newcastle upon Tyne, United Kingdom                                                                   |
| 17:00 - 17:00        | <b>22P - Machine learning model for prediction of EGFR mutation in NSCLC patients from PET radiomic features</b><br><u>Akanksha Minj</u> , JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India                                          |
| 17:00 - 17:00        | <b>23P - AI-assisted dosimetry for [177Lu] DOTATATE therapy in Mexico</b><br><u>Amy Husband</u> , Hospital Angeles Pedregal, Mexico City, Mexico                                                                                                                                    |
| 17:00 - 17:00        | <b>25P - Genomic landscape and prognostic value of circulating tumor DNA (ctDNA) in pancreatic ductal adenocarcinoma (PDAC): A real-world cohort of 541 patients</b><br><u>Sarah Blanchet-Deverly</u> , Gustave Roussy - Cancer Campus, Villejuif, France                           |
| 17:00 - 17:00        | <b>26P - Dynamic circulating tumor DNA (ctDNA) kinetics refine static HRD profiling to predict PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOC)</b><br><u>Ashmita Ghosh</u> , Ruby General Hospital, Kolkata, India                                            |
| 17:00 - 17:00        | <b>27P - Combined MSI marker and tumor variant tracking in ctDNA from MSI colorectal cancer</b><br><u>Anis Alachkar</u> , Poitiers University Hospital, Poitiers, France                                                                                                            |



- 17:00 - 17:00      **29P - OTX1 DNA methylation as a liquid biopsy biomarker in advanced NSCLC: A comparative evaluation of bisulfite conversion and methylation-sensitive restriction enzyme workflows**  
Christina Soes Andersen, Zealand University Hospital Naestved, Naestved, Denmark
- 17:00 - 17:00      **30P - A cell-free DNA-inspired NGS panel for somatic BRCA1 and BRCA2 molecular testing in prostate FFPE needle biopsies**  
Julie Noer, Zealand University Hospital, Naestved, Denmark
- 17:00 - 17:00      **34P - Clinical utility of next-generation sequencing in biliary tract cancer: ERBB2 alterations, HER2 discordance, and outcomes with HER2-targeted therapy**  
Hanbaek Yi, SNUH - Seoul National University Hospital, Seoul, Republic of Korea
- 17:00 - 17:00      **35P - Next generation diagnostics: Photoelectrochemical detection of DPYD mutations via LNA-Mediated recognition and HCR signal amplification**  
Anouk Peymen, University of Antwerp, Antwerpen, Belgium
- 17:00 - 17:00      **36P - Tumour-only microsatellite instability analysis from routine targeted next-generation sequencing in colorectal cancer**  
Madison Leask, Barts Health NHS Trust, London, United Kingdom
- 17:00 - 17:00      **37P - Clinical implementation and validation of a germline next-generation sequencing panel for cancer susceptibility testing**  
Charlotte Flanagan, The Royal Marsden Hospital (Sutton), Sutton, United Kingdom
- 17:00 - 17:00      **38P - Real-world effectiveness and tolerability of the PARP inhibitor olaparib in metastatic breast cancer patients with germline PALB2 and somatic BRCA1/2 mutations**  
Myrto Kastrisiou, Royal Marsden Hospital, London, United Kingdom
- 17:00 - 17:00      **40P - Genomic concordance between small extracellular vesicle-derived DNA and parental tumor cells revealed by whole-genome sequencing**  
Benjamin David, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, France
- 17:00 - 17:00      **42P - B7-H3 defines an aggressive molecular subtype of pleural mesothelioma characterized by immune exclusion and EMT**  
Silvia Marchesi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
- 17:00 - 17:00      **44P - Pan-cancer transcriptomic profiling of spatial ecotypes predicts response to immune checkpoint inhibitors in solid tumors**  
Changbin Zhu, Amoy Diagnostics Co., Ltd., Xiamen, China
- 17:00 - 17:00      **45P - Synergistic prognostic value of Immunoscore and preoperative carcinoembryonic antigen for enhanced risk stratification in stage III colorectal cancer**  
Chih-Yung Yang, Taipei City Hospital - Renai Branch, Taipei City, Taiwan



- 17:00 - 17:00      **48P - Laser capture microdissection-based proteomics to identify immunotherapy response signatures in high-grade neuroendocrine neoplasms**  
Patrick Mcgarrah, Mayo Clinic - Rochester, Rochester, United States of America
- 17:00 - 17:00      **51P - Proteomic profiling of small extracellular vesicles reveals biomarkers of chemoradiotherapy response in head and neck cancer**  
Igor Fagundes, Barretos Cancer Hospital, Barretos, Brazil
- 17:00 - 17:00      **52P - Detection and tracking of human papillomavirus circulating tumor DNA assessment in Chinese cervical cancer receiving curative treatment**  
Yuping Hao, Amoy Diagnostics Co., Ltd., Xiamen, China
- 17:00 - 17:00      **53P - Super-ddCapture enables ultra-sensitive MRD detection at single variant level in driver mutant NSCLC: Analytic validation and concordance to bespoke strategy**  
Xing Li, Amoy Diagnostics Co., Ltd., Xiamen, China
- 17:00 - 17:00      **54P - Prognostic evaluation of driver genome architectures and minimal residual disease (MRD) in early-stage colorectal cancer (CRC)**  
Christopher Sng, ICR - Institute of Cancer Research, London, United Kingdom
- 17:00 - 17:00      **55P - Cellular migratory scaling stratifies glioblastoma survival: PTEN amino acid substitutions as pro-invasive drivers**  
Chiara Maria Mazzanti, Fondazione Pisana per la Scienza ONLUS, San Giuliano Terme, Italy
- 17:00 - 17:00      **56P - Circulating protein component captures tumor biology and is a prognostic marker in pediatric osteosarcoma**  
Baptiste Audinot, Institut Gustave Roussy, Villejuif, France
- 17:00 - 17:00      **57P - SPARK: Real-time single-cell profiling from FFPE samples to inform treatment strategies in advanced solid tumors**  
Floriane Izarn, Centre Léon Bérard, Lyon, France
- 17:00 - 17:00      **58P - The distribution of homologous recombination deficiency across cancer types, revealing novel treatment opportunities?**  
Nina Foerster-Massey, Oslo University Hospital, Oslo, Norway
- 17:00 - 17:00      **59P - Impact of molecular classification on adjuvant treatment selection in non-metastatic endometrial cancer: A real-world precision oncology study from India**  
Goutham Katta Charu, Danja, Hyderabad, India
- 17:00 - 17:00      **60P - Different gut microbiota (GM) species and their association with clinical outcomes in pleural mesothelioma (PM)**  
Luigi Cerbone, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy



|               |                                                                                                                                                                                                                                                                                                       |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17:00 - 17:00 | <p><b>61P - TROP2 expression correlates with drug sensitivity in tumor organoids of metastatic colorectal cancer</b></p> <p><u>Christian Kranjec</u>, Institute for Cancer Research - Oslo University Hospital, Oslo, Norway</p>                                                                      |
| 17:00 - 17:00 | <p><b>62P - FGFR2 and favorable survival outcomes in resected poorly cohesive cell gastric cancer: Analysis from FGFR2 protein overexpression and genetic variation</b></p> <p><u>Jong Gwang Kim</u>, KNU - Kyungpook National University School of Medicine, Daegu, Republic of Korea</p>            |
| 17:00 - 17:00 | <p><b>63P - Integrating host inflammatory biology with molecular selection to predict durable PARP inhibitor benefit: A three-center real-world study</b></p> <p><u>Suleyman Guzel</u>, Istanbul University-Cerrahpasa - Faculty of Medicine, Istanbul, Türkiye</p>                                   |
| 17:00 - 17:00 | <p><b>64P - Ensemble machine learning identifies an externally validated 17-gene signature predicting neoadjuvant chemotherapy response in breast cancer</b></p> <p><u>Chrysovalantis Voutouri</u>, University of Cyprus, Nicosia, Cyprus</p>                                                         |
| 17:00 - 17:00 | <p><b>65P - Cost-benefit analysis of reflex biomarker testing to improve precision oncology delivery in Indian cancer patients: A prospective controlled implementation study</b></p> <p><u>Goutham Katta Charu</u>, Danja, Hyderabad, India</p>                                                      |
| 17:00 - 17:00 | <p><b>66P - A clinically informative nine miRNA signature provides independent prognostic stratification beyond conventional staging in lung adenocarcinoma</b></p> <p><u>Meliha Kara</u>, Istanbul University-Cerrahpasa - Faculty of Medicine, Istanbul, Türkiye</p>                                |
| 17:00 - 17:00 | <p><b>68P - Dynamic <math>\gamma</math>-H2AX foci-based molecular monitoring of chemotherapy response in breast cancer within a precision oncology framework</b></p> <p><u>Marzhan Aitmagambetova</u>, West Kazakhstan State Medical University named after. A.I. M. Ospanova, Aktobe, Kazakhstan</p> |
| 17:00 - 17:00 | <p><b>70P - Prevalence of PTEN/PIK3CA/AKT1 alterations in TMB-high metastatic castration-resistant prostate cancer</b></p> <p><u>Leo Edlinger</u>, Medical University of Graz, Graz, Austria</p>                                                                                                      |
| 17:00 - 17:00 | <p><b>71P - Functional TRK and ROS1 drug target activation analysis in metastatic colorectal cancer: Implications for targeted therapy in pretreated patients</b></p> <p><u>Timothy Cannon</u>, Inova Schar Cancer Institute, Fairfax, United States of America</p>                                   |
| 17:00 - 17:00 | <p><b>72P - Molecular characterization of lncRNA-regulated pathways in metastatic prostate cancer</b></p> <p><u>Poornima Verma</u>, Sanjay Gandhi Postgraduate Institute of Medical Sciences, lucknow, India</p>                                                                                      |
| 17:00 - 17:00 | <p><b>73P - Multiple myeloma displays heightened sensitivity to protein synthesis stress via mTORC1 signalling</b></p> <p><u>Somnath Ghosal</u>, RKMVERI - Ramakrishna Mission Vivekananda Educational and Research Institute, Howrah, India</p>                                                      |



- 17:00 - 17:00 **75P - Pan-RAS inhibition by RMC-7977 enhances bortezomib sensitivity via protein synthesis and wee1 suppression**  
Somnath Ghosal, RKMVERI - Ramakrishna Mission Vivekananda Educational and Research Institute, Howrah, India
- 17:00 - 17:00 **78P - USMB-mediated DYRK1A silencing rewires cell-cycle dependence and sensitizes non-small cell lung cancer to CDK4/6 blockade**  
Muhammad Shakeeb Sharif, Scuola Superiore Meridionale, Naples, Italy
- 17:00 - 17:00 **79P - Impact of genetic variants of complex II-subunit on renal cell carcinoma characteristics**  
Marek Krátký, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic
- 17:00 - 17:00 **81P - Nutritional intervention modulates serum protein profile and inflammatory cytokines in breast cancer patients on aromatase inhibitors**  
Marijana Kovacic, Institute for Medical Research - Belgrade University, Belgrade, Serbia
- 17:00 - 17:00 **82P - A novel LINC00657-miR-17-5p/eIF2α regulatory circuit promotes ethanol-induced aggressive hepatocellular carcinoma**  
Himanshi Goyal, PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, India
- 17:00 - 17:00 **83P - Functional characterisation of novel drivers of chromosomal instability in triple-negative breast cancer**  
Tristan Kennedy, University of Oxford, Oxford, United Kingdom
- 17:00 - 17:00 **84P - The VDAC1-VDAC1P8 regulatory axis in cancer**  
Sara D'Amato, Università degli Studi di Catania - Torre Biologica, Catania, Italy
- 17:00 - 17:00 **85P - Long-term follow-up of a regional molecular tumor board: Alignment with the ESMO Precision Oncology Working Group recommendations**  
Cedric Van Marcke De Lummen, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, Belgium
- 17:00 - 17:00 **86P - Molecular tumor board-guided treatment in advanced solid tumors: Experience from a Portuguese cancer center**  
Frederico Sarmento, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, Portugal
- 17:00 - 17:00 **87P - Implementation of an automated clinically integrated secondary and tertiary analysis pipeline for routine NGS-based molecular diagnostics in a comprehensive cancer centre**  
Chiara Notturmo Granieri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy



- 17:00 - 17:00      **88P - Clinical impact of NGS-guided therapy in metastatic lung cancer in private practice**  
Anna Flavia Andrade, Oncomed - Clinica de Prevencao e Tratamento de Doencas Neoplasicas, Belo Horizonte, Brazil
- 17:00 - 17:00      **89P - Added clinical value of comprehensive genomic profiling in patients with advanced non-small cell lung cancer previously tested by targeted NGS panels, evaluated by the ESMO Oncology scale of clinical actionability for molecular targets (ESCAT) classification**  
Nina Giuliani, Aalborg University Hospital, Aalborg, Denmark
- 17:00 - 17:00      **90P - Automated data-integration middleware for liquid biopsy molecular profiling in a comprehensive cancer centre**  
Alessia Preziosi, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 17:00 - 17:00      **92P - Comparative study of 18F-FDG PET/CT and MRI in the diagnosis of primary brain tumors**  
Rajesh Kumar, AIIMS - All India Institute of Medical Sciences, Jodhpur, Jodhpur, India
- 17:00 - 17:00      **94P - Patient-centered precision medicine education in a low-resource setting: Lessons from a community-based breast cancer advocacy program in Nigeria**  
Ethel Olomu, Engraced Life Foundation, Lagos, Nigeria
- 17:00 - 17:00      **95P - Spatial proteomic signatures suggest distinct clinical phenotypes in KRAS-mutant metastatic NSCLC**  
Alice Ilari, Fondazione IRCCS San Gerardo dei Tintori Monza, Monza, Italy
- 17:00 - 17:00      **96P - Single-cell multiome profiling of ecDNA-associated states in lung cancer**  
Jorge Martin-Arana, UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom
- 17:00 - 17:00      **97P - Understanding the spatial landscape of the epithelial-stromal interface in oral potentially malignant disorders**  
Neerada Meenakshi Warriar, Mazumdar Shaw Medical Foundation, Bangalore, India
- 17:00 - 17:00      **98P - Identification of markers of gemcitabine-resistance in TNBC PDX, using single-cell RNA-sequencing**  
Sandrine Busque, Goodman Cancer Research Center - McGill University, Montreal, Canada
- 17:00 - 17:00      **99P - Spatially resolved transcriptomic architecture of the tumor microenvironment in chewing tobacco-related oral squamous cell carcinoma stratified by PD-L1 expression**  
Vijay Srinivasalu, Sakra World Hospital, Bangalore, India
- 17:00 - 17:00      **101P - Spatial deconvolution of neuro-immune-tumor crosstalk in central nervous system lymphoma**  
Quan Shi, Universitätsklinikum Essen, Essen, Germany



- 17:00 - 17:00      **102P - Spatial transcriptomic profiling of the tumor immune microenvironment in LSD1 inhibitor-based immunotherapy in triple-negative breast cancer using CosMx single-cell imaging**  
Jabed Iqbal, SGH - Singapore General Hospital / SingHealth-Academia, Singapore, Singapore
- 17:00 - 17:00      **104P - Cross-dataset transcriptomic profiling of anaplastic versus papillary thyroid carcinoma**  
Thalita Senen, LSTM - Liverpool School of Tropical Medicine, Liverpool, United Kingdom
- 17:00 - 17:00      **105P - Global biotype profiling reveals long non-coding RNA dominance in the cell-free transcriptome of acute myeloid leukemia**  
Deepshi Thakral, AIIMS - All India Institute of Medical Sciences, NEW DELHI, India
- 17:00 - 17:00      **107P - Genomic and transcriptomic profiling of chronic lymphocytic leukemia**  
Arpine Minasyan, Institute of Molecular Biology NAS RA, Yerevan, Armenia
- 17:00 - 17:00      **108P - LSD1 co-occupies HIF1A-bound enhancers at hypoxia-responsive loci to drive metabolic reprogramming in triple-negative breast cancer**  
Jabed Iqbal, SGH - Singapore General Hospital / SingHealth-Academia, Singapore, Singapore
- 17:00 - 17:00      **109P - Plasma proteomics identify circulating mediators of cancer-associated sarcopenia**  
Xinran Song, Institut Gustave Roussy, Villejuif, France
- 17:00 - 17:00      **110P - Cancer type-specific genomic routes to metastatic dissemination**  
Luc Morris, Memorial Sloan Kettering Cancer Center, New York, United States of America
- 17:00 - 17:00      **111P - Low-coverage WGS DNA methylation sequencing for sarcoma classification from FFPE tissue**  
Sebastiaan Van Den Berg, UMC-University Medical Center Utrecht, Utrecht, Netherlands
- 17:00 - 17:00      **112P - Decoding systemic immune reprogramming in glioblastoma for patient stratification and therapeutic targeting**  
Alessandro Michelucci, Luxembourg Institute of Health, Luxembourg, Luxembourg
- 17:00 - 17:00      **115P - Intra-patient genomic biomarker heterogeneity in diagnostic samples from de novo metastatic hormone-sensitive prostate cancer (mHSPC)**  
Andrew Murtha, University of British Columbia, Vancouver, Canada
- 17:00 - 17:00      **116P - KMT2D mutation in small cell lung cancer: Molecular consequences and therapeutic vulnerabilities**  
Sayantani Mitra, University of Cologne, Cologne, Germany
- 17:00 - 17:00      **117P - Platform for structured capture and sharing of exceptional clinical-genomic observations in oncology: Deployment and first real-world cohort**  
Semih Dogan, Gustave Roussy - Cancer Campus, Villejuif, France



- 17:00 - 17:00      **118P - Integrating molecular biomarkers for selecting immunotherapy and targeted agents in oral cancers: Toward precision immuno-targeted therapies for oral cancer**  
Ravi Shankar Bellala, Omega Hospitals , Visakhapatnam, Visakhapatnam, India
- 17:00 - 17:00      **119P - Outcomes and safety of chemosaturation with percutaneous hepatic perfusion (CS-PHP) in liver-dominant metastatic uveal melanoma: Impact of molecular profiling on survival**  
Hebatalla Ismail, St Vincents University Hospital, UDC Cancer Centre, Dublin, Ireland
- 17:00 - 17:00      **120P - Validation of a capture-based next-generation sequencing assay for IG/TR clonality assessment in an NHS diagnostic laboratory**  
Charlotte Flanagan, The Royal Marsden Hospital (Sutton), Sutton, United Kingdom
- 17:00 - 17:00      **121P - Multi-omic characterisation of non-oncogene addicted non-small cell lung cancer**  
Matt Church, The University of Manchester, Manchester, United Kingdom
- 17:00 - 17:00      **122P - A digital implementation guide to accelerate comprehensive genomic profiling: Development, launch and early uptake**  
Clare Jones, Avalere Health, London, United Kingdom
- 17:00 - 17:00      **123P - Multimodal nutrition intervention in advanced non-small cell lung cancer (NSCLC): Preliminary results from the multi-omics high eicosapentaenoic acid and PROtein (HEPRO) trial**  
Imanuely Gonçalves, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Rio de Janeiro, Brazil
- 17:00 - 17:00      **125P - Therapeutic rescue of acquired resistance to BRAF/EGFR inhibition by combination treatment in colorectal cancer cell lines**  
Kushtrim Kryeziu, Institute for Cancer Research - Oslo University Hospital, Oslo, Norway
- 17:00 - 17:00      **127P - Tumor-selective oncolytic adenovirus encoding secretory CES2 for enhanced prodrug activation and immune modulation in ovarian cancer**  
Abhishek Swarnakar, CSIR - Indian Institute of Chemical Biology, KOLKATA, India
- 17:00 - 17:00      **129P - Histology-specific immune ecologies of TP53-altered tumours in TCGA**  
Edwin Quispe Bellido, NEXT Oncology. Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcon, Spain
- 17:00 - 17:00      **130P - First-in-class IKKα inhibitor SU1644 as a novel therapeutic strategy for advanced prostate cancer**  
Giang Lam, Adelaide University, Adelaide, Australia



17:00 - 17:00

**131P - Novel bioinformatic algorithm enables robust detection of MTAP homozygous deletion in FFPE samples with low tumor purity**

Luoyao Wan, Amoy Diagnostics Co., Ltd., Xiamen, China

17:00 - 17:00

**133P - Germline exome profiling of medication related osteonecrosis of the jaw in breast cancer patients: Replication of candidate genes and exploratory pathway analysis**

Aysha Al-Balushi, SQCCCRC - Sultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, Oman



11.09.2026

|                      |                                                                                     |                   |
|----------------------|-------------------------------------------------------------------------------------|-------------------|
| <b>08:45 - 10:00</b> | <b>Cancer and its microenvironment interface</b><br>Moderation: Eduard Porta, Spain | <b>Auditorium</b> |
|----------------------|-------------------------------------------------------------------------------------|-------------------|

|               |                                                                                                                                                     |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:45 - 09:00 | <b>Cancer neuroscience beyond primary brain tumors</b><br><a href="#">Simon Renders</a> , DKFZ - German Cancer Research Center, Heidelberg, Germany |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                               |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| 09:00 - 09:15 | <b>The role of immune hubs in cancer</b><br><a href="#">Eduard Porta</a> , Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                                                            |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09:15 - 09:30 | <b>Waking up with a STING: Immune evasion during reactivation from dormancy</b><br><a href="#">Benjamin Izar</a> , Columbia University, New York, United States of America |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                            |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| 09:30 - 09:45 | <b>Tumor-driven myelopoiesis and immune reprogramming</b><br><a href="#">Nicoletta Caronni</a> , IRCCS Ospedale San Raffaele, Milan, Italy |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------|

|               |                |
|---------------|----------------|
| 09:45 - 10:00 | <b>Q&amp;A</b> |
|---------------|----------------|

|                      |                     |              |
|----------------------|---------------------|--------------|
| <b>10:00 - 10:30</b> | <b>Coffee break</b> | <b>Foyer</b> |
|----------------------|---------------------|--------------|

|                      |                                                                                                                 |                   |
|----------------------|-----------------------------------------------------------------------------------------------------------------|-------------------|
| <b>10:30 - 12:00</b> | <b>Rapid Oral session</b><br>Moderation: Lisa Derosa, France; Joaquin Mateo, Spain; Nnenna Kanu, United Kingdom | <b>Auditorium</b> |
|----------------------|-----------------------------------------------------------------------------------------------------------------|-------------------|

|               |                                                                                                                                                                                                                                                                                                                        |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10:30 - 10:35 | <b>10RO - MethyGlio: Interpretable deep learning enables hierarchical glioma methylome stratification with cross-platform validation and nomination of circulating cfDNA methylation candidates</b><br><a href="#">Aierpati Maimaiti</a> , The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                                                                           |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10:35 - 10:40 | <b>11RO - FMT-induced faecal IgG binding links gut microbial immunity to immunotherapy response</b><br><a href="#">Andrew Almonte</a> , Gustave Roussy - Cancer Campus, Villejuif, France |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                                                   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10:40 - 10:45 | <b>15RO - (Epi)genomic characterization of non-Hodgkin lymphoma through long-read sequencing</b><br><a href="#">Amber Verhasselt</a> , KU Leuven, Leuven, Belgium |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|               |                            |
|---------------|----------------------------|
| 10:45 - 11:00 | <b>Wrap up and Q&amp;A</b> |
|---------------|----------------------------|

|               |                                                                                                                                                                                                                                        |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11:00 - 11:05 | <b>12RO - De novo development and verification of a multi-gene expression profile for recurrence prediction in Chinese ER+/HER2-negative breast cancer</b><br><a href="#">Changbin Zhu</a> , Amoy Diagnostics Co., Ltd., Xiamen, China |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|               |                                                                                                                                                                                                                        |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11:05 - 11:10 | <b>16RO - Triple-negative breast cancer rapidly recurring after neoadjuvant chemotherapy: Genomic and immunologic profiling</b><br><a href="#">Nina Radosevic-Robin</a> , Centre Jean Perrin, Clermont-Ferrand, France |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|



11:10 - 11:15 **13RO - Follow-up of circulating circulating tumour DNA in patients with borderline resectable pancreatic ductal adenocarcinoma included in the PANDAS-PRODIGE 44 trial: Trans-PANDAS study**  
Cassandra Michel, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, France

11:15 - 11:30 **Wrap up and Q&A**

11:30 - 11:35 **14RO - Nationwide implementation of comprehensive genomic profiling in advanced cancer: Real-world results from IMPRESS-Norway**  
Siri Strand, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway

11:35 - 11:40 **17RO - Comprehensive genomic profiling of pleural mesothelioma unveils potential targets within a molecular tumor board framework**  
Daniele Lorenzini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

11:40 - 11:45 **18RO - The genomic landscape of therapy-related myeloid neoplasms following PARP inhibitor therapy in ovarian cancer**  
Yoann Pradat, Gustave Roussy - Cancer Campus, Villejuif, France

11:45 - 12:00 **Wrap up and Q&A**

|               |                                                                                                    |                |
|---------------|----------------------------------------------------------------------------------------------------|----------------|
| 12:00 - 13:00 | <b>Lunch</b>                                                                                       | <b>Foyer</b>   |
| 12:15 - 13:00 | <b>YO mentorship session</b><br>Moderation: Emre Kocakavuk, Germany; Lucy Faulkner, United Kingdom | <b>Gallery</b> |

12:15 - 13:00 **Career Pathways in Precision Oncology**  
Jeanne Tie<sup>1</sup>, Geoff Macintyre<sup>2</sup>, <sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, Australia, <sup>2</sup>CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

|               |                                                                                                                      |                   |
|---------------|----------------------------------------------------------------------------------------------------------------------|-------------------|
| 13:00 - 13:30 | <b>Keynote lecture: Cancer and the peripheral nervous system</b><br>Moderation: Mariam Jamal-Hanjani, United Kingdom | <b>Auditorium</b> |
|---------------|----------------------------------------------------------------------------------------------------------------------|-------------------|

13:00 - 13:05 **Introduction**  
Mariam Jamal-Hanjani, UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom

13:05 - 13:30 **Cancer and the peripheral nervous system**  
Leanne Li, The Francis Crick Institute, London, United Kingdom

|               |                                                                                                                                     |                   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| 13:40 - 14:55 | <b>Before the tumour: New frontiers in cancer interception</b><br>Moderation: Sarah Blagden, United Kingdom; Marine Fidelle, France | <b>Auditorium</b> |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------|

13:40 - 13:55 **Generating a pipeline of cancer prevention vaccines**  
Sarah Blagden, Churchill Hospital, Oxford, United Kingdom



|               |                                                                                                                                                                                                                |                   |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| 13:55 - 14:10 | <b>Inflammation to cancer transition predicted by multiomic biomarkers for cancer interception in at risk individuals</b><br><u>Marine Fidelle</u> , Institut Gustave Roussy, Villejuif, France                |                   |
| 14:10 - 14:25 | <b>Genome-wide cfDNA fragmentation for early detection of cancer</b><br><u>Victor Velculescu</u> , Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America |                   |
| 14:25 - 14:40 | <b>Cancer interception/ prevention based on the gut microbiota</b><br><u>Gianmarco Piccinno</u> , Università degli Studi di Trento, Trento, Italy                                                              |                   |
| 14:40 - 14:55 | <b>Q&amp;A</b>                                                                                                                                                                                                 |                   |
| 14:55 - 15:15 | <b>Coffee break</b>                                                                                                                                                                                            | <b>Foyer</b>      |
| 15:15 - 16:30 | <b>Circulating biomarkers in cancer</b><br>Moderation: Alexander Wyatt, Canada; Caroline Dive, United Kingdom                                                                                                  | <b>Auditorium</b> |
| 15:15 - 15:30 | <b>Clinical applications of ctDNA as a residual disease biomarker</b><br><u>Jeanne Tie</u> , Peter MacCallum Cancer Centre, Melbourne, Australia                                                               |                   |
| 15:30 - 15:45 | <b>Circulating biomarkers to optimise treatment of Ewings sarcoma</b><br><u>Eleni Tomazou</u> , St. Anna Children's Cancer Research Institute CCRI, Vienna, Austria                                            |                   |
| 15:45 - 16:00 | <b>Tracking tumour and immune changes with cell-free DNA</b><br><u>Florent Mouliere</u> , Cancer Research UK Manchester Institute - The University of Manchester, Macclesfield, United Kingdom                 |                   |
| 16:00 - 16:15 | <b>Precision genotyping of metastatic cancer with liquid biopsy</b><br><u>Alexander Wyatt</u> , The University of British Columbia, Vancouver, Canada                                                          |                   |
| 16:15 - 16:30 | <b>Q&amp;A</b>                                                                                                                                                                                                 |                   |